Willingness to pay for a cure in patients with chronic gout

Medical Decision Making

Volumn 28, Issue 4, 2008, Pages 606-613

  Khanna, Dinesh ^a,b,c,d   Ahmed, Mansoor ^a,c   Yontz, Dustin ^a   Ginsburg, Shaari S ^a,c   Tsevat, Joel ^a,b,c  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF CINCINNATI   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Cost benefit analysis; Gout; Health related quality of life; Willingness to pay

Indexed keywords

ALLOPURINOL; COLCHICINE; NONSTEROID ANTIINFLAMMATORY AGENT; PREDNISONE;

ADULT; AFRICAN AMERICAN; AGE; AGED; ARTICLE; CARDIOVASCULAR DISEASE; CAUCASIAN; CHRONIC DISEASE; COMORBIDITY; COST BENEFIT ANALYSIS; DEMOGRAPHY; DIABETES MELLITUS; FEMALE; GOUT; HEALTH CARE COST; HEALTH INSURANCE; HEALTH STATUS; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; INCOME; INTERVIEW; MAJOR CLINICAL STUDY; MALE; MEDICAL DECISION MAKING; PERIPHERAL VASCULAR DISEASE; QUALITY OF LIFE; STATISTICAL ANALYSIS; WILLINGNESS TO PAY;

CHRONIC DISEASE; DRUG COSTS; FEMALE; FINANCING, PERSONAL; GOUT; GOUT SUPPRESSANTS; HEALTH EXPENDITURES; HUMANS; INCOME; MALE; MIDDLE AGED; QUESTIONNAIRES; SOCIOECONOMIC FACTORS;

EID: 47249158539     PISSN: 0272989X     EISSN: 1552681X     Source Type: Journal    
DOI: 10.1177/0272989X08315252     Document Type: Article

References (36)

1. Saag KG, Choi H. Epidemiology, risk factors, and lifestyle modifications for gout. Arthritis Res Ther. 2006 ; 8 (suppl 1). S2.
2. Brook RA, Kleinman NL, Patel PA, et al. The economic burden of gout on an employed population. Curr Med Res Opin. 2006 ; 22 (7). 1381-9.
3. Kim KY, Ralph SH, Hunsche E., Wertheimer AI, Kong SX A literature review of the epidemiology and treatment of acute gout. Clin Ther. 2003 ; 25 (6). 1593-617.
4. Brook RA, Kleinman NL, Patel PA, et al. The economic burden of gout on an employed population. Curr Med Res Opin. 2006 ; 22 (7). 1381-9.
5. Kleinman NL, Brook RA, Patel PA, et al. The impact of gout on work absence and productivity. Value Health. 2007 ; 10 (4). 1-7.
6. Gyrd-Hansen D. Willingness to pay for a QALY: theoretical and methodological issues. Pharmacoeconomics. 2005 ; 23 (5). 423-32.
7. Drummond M, Sculpher M, Torrance GW, O'Brian BJ, Stoddart G, eds. Cost-benefit analysis. In: Methods for the Economic Evaluation of Health Care Programmes. 3 rd ed. Oxford (UK): Oxford Medical Publications ; 2005. p 211-45.
8. Bala MV, Mauskopf JA, Wood LL Willingness to pay as a measure of health benefits. Pharmacoeconomics. 1999 ; 15 (1). 9-18.
9. Wallace SL, Robinson H., Masi AT, Decker JL, McCarty DJ, Yu TF Preliminary criteria for the classification of the acute arthritis of primary gout. Arthritis Rheum. 1977 ; 20 (3). 895-900.
10. Hirsch J., Lee S., Terkeltaub R., et al. Evaluation of the psychometric properties of a gout-specific patient reported outcomes (PRO) instrument [abstract]. Arthritis Rheum. 2006 ; 54 (9). S102.
11. Ware J., Kosinski M., Dewey J. How to Score Version Two of the SF-36 Health Survey. Lincoln (RI): QualityMetric Incorporated ; 2000.
12. Ware JE Jr, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care. 1992 ; 30 (6). 473-83.
13. Ware JE Jr, Kosinki M., Keller S. SF-36 Physical and Mental Health Summary Scales: A User's Manual. Boston: Health Institute, New England Medical Center ; 1994.
14. US Department of Labor Bureau of Labor Statistics. Consumer price index. Available from: URL: http://data.bls.gov/cgi-bin/surveymost?cu. Accessed April 2007.
15. Slothuus U., Brooks RG Willingness to pay in arthritis: a Danish contribution. Rheumatology (Oxford). 2000 ; 39 (7). 791-9.
16. Yasunaga H., Ide H., Imamura T., Ohe K. Willingness to pay for health care services in common cold, retinal detachment, and myocardiac infarction: an Internet survey in Japan. BMC Health Serv Res. 2006 ; 6: 12.
17. Gueylard CD, LeLorier J. A willingness-to-pay assessment of parents' preference for shorter duration treatment of acute otitis media in children. Pharmacoeconomics. 2005 ; 23 (12). 1243-55.
18. van den Bosch JE, Bonsel GJ, Moons KG, Kalkman CJ Effect of postoperative experiences on willingness to pay to avoid postoperative pain, nausea, and vomiting. Anesthesiology. 2006 ; 104 (5). 1033-9.
19. Ramsey SD, Sullivan SD, Psaty BM, Patrick DL Willingness to pay for antihypertensive care: evidence from a staff-model HMO. Soc Sci Med. 1997 ; 44 (12). 1911-7.
20. Johannesson M. Economic evaluation of lipid lowering-a feasibility test of the contingent valuation approach. Health Policy. 1992 ; 20 (3). 309-20.
21. Schiffner R., Schiffner-Rohe J., Gerstenhauer M., Hofstadter F., Landthaler M., Stolz W. Willingness to pay and time trade-off: sensitive to changes of quality of life in psoriasis patients? Br J Dermatol. 2003 ; 148 (6). 1153-60.
22. Cross MJ, March LM, Lapsley HM, et al. Determinants of willingness to pay for hip and knee joint replacement surgery for osteoarthritis. Rheumatology (Oxford). 2000 ; 39 (11). 1242-8.
23. Frew EJ, Whynes DK, Wolstenholme JL Eliciting willingness to pay: comparing closed-ended with open-ended and payment scale formats. Med Decis Making. 2003 ; 23 (2). 150-9.
24. Bayoumi AM The measurement of contingent valuation for health economics. Pharmacoeconomics. 2004 ; 22 (11). 691-700. 25. Frew EJ, Wolstenholme JL, Whynes DK Comparing willingness-to-pay: bidding game format versus open-ended and payment scale formats. Health Policy. 2004 ; 68 (3). 289-98.
25. Ryan M., Scott DA, Donaldson C. Valuing health care using willingness to pay: a comparison of the payment card and dichotomous choice methods. J Health Econ. 2004 ; 23 (2). 237-58.
26. Sarawate CA, Brewer KK, Yang W., et al. Gout medication treatment patterns and adherence to standards of care from a managed care perspective. Mayo Clin Proc. 2006 ; 81 (7). 925-34.
27. Sarawate CA, Patel PA, Schumacher HR, Yang W., Brewer KK, Bakst AW Serum urate levels and gout flares: analysis from managed care data. J Clin Rheumatol. 2006 ; 12 (2). 61-5.
28. Riedel AA, Nelson M., Joseph-Ridge N., Wallace K., MacDonald P., Becker M. Compliance with allopurinol therapy among managed care enrollees with gout: a retrospective analysis of administrative claims. J Rheumatol. 2004 ; 31 (8). 1575-81.
29. Riedel AA, Nelson M., Joseph-Ridge N., Wallace K., MacDonald P., Becker M. Compliance with allopurinol therapy among managed care enrollees with gout: a retrospective analysis of administrative claims. J Rheumatol. 2004 ; 31 (8). 1575-81.
30. Becker MA, Schumacher HR Jr, Wortmann RL, et al. Febuxostat compared with allopurinol in patients with hyperuricemia and gout. N Engl J Med. 2005 ; 353 (23). 2450-61.
31. Choi HK, Ford ES, Li C., Curhan G. Prevalence of the metabolic syndrome in patients with gout: the Third National Health and Nutrition Examination Survey. Arthritis Rheum. 2007 ; 57 (1). 109-15.
32. Borstad GC, Bryant LR, Abel MP, Scroggie DA, Harris MD, Alloway JA Colchicine for prophylaxis of acute flares when initiating allopurinol for chronic gouty arthritis. J Rheumatol. 2004 ; 31 (12). 2429-32.
33. Choi HK, Ford ES, Li C., Curhan G. Prevalence of the metabolic syndrome in patients with gout: the Third National Health and Nutrition Examination Survey. Arthritis Rheum. 2007 ; 57 (1). 109-15. 35. Drugstore.com. Available at: URL: www.drugstore.com. Accessed 20 July 2007.
34. Detsky AS, Laupacis A. Relevance of cost-effectiveness analysis to clinicians and policy makers. JAMA. 2007 ; 298 (2). 221-4.
35. Russell LB, Siegel JE, Daniels N., Gold MR, Luce B., Mandelblatt J. Cost-effectiveness analysis as guide to resource allocation in health: roles and limitation. In: Gold MR, Siegel JE, Russell LB, Weinstein MC, eds. Cost-Effectiveness in Health and Medicine. Oxford (UK): Oxford University Press ; 1996. p 3-24.
36. O'Brien B., Gafni A. When do the ''dollars'' make sense? Toward a conceptual framework for contingent valuation studies in health care. Med Decis Making. 1996 ; 16 (3). 288-99.